Background Artefenomel (OZ439) is a novel synthetic trioxolane with improved pharmacokinetic properties compared with other antimalarial drugs with the artemisinin pharmacophore. Artefenomel has been generally well tolerated in volunteers at doses up to 1600 mg and is being developed as a partner drug in an antimalarial combination treatment. We investigated the effi cacy, tolerability, and pharmacokinetics of artefenomel at diff erent doses in patients with Plasmodium falciparum or Plasmodium vivax malaria.
Introduction
Malaria is the most important parasitic disease in people, and a major cause of morbidity and mortality in tropical regions. WHO has declared malaria control a global development priority and has changed its focus from containment and control to elimination. 1 Drug resistance in Plasmodium species poses a major obstacle. Resistance in Plasmodium falciparum, the main cause of malarial death, has rendered several fi rst-line antimalarial drugs (fi rst chloroquine, then sulfadoxine-pyrimethamine, and in some areas amodiaquine) largely ineff ective. Since 2005, WHO has recommended artemisinin-based combination therapy as the fi rst-line treatment for falciparum malaria. 2 Artemisinin and its derivatives are the most potent and rapidly acting antimalarial drugs available. 3 The peroxidic pharmacophore is essential for their activity. 4 The antimalarial activities of artemisinin derivatives are characterised by high parasite killing rates and broad-stage specifi city of antimalarial action. These antimalarial drugs produce more rapid clinical and parasitological responses than other classes of available drugs. 5 However, they are eliminated rapidly (half-lives <1 h), which necessitated a treatment course of 7 days when they were given alone for falciparum malaria. Combination with a more slowly eliminated partner drug has allowed for 3-day courses of artemisinin-based combination therapy, improved treatment outcomes, and enhanced patient adherence. 6, 7 WHO recommends that new antimalarial drugs should be deployed as combination treatments to provide mutual protection against resistance. 2, 8 Unfortunately, artemisinin resistance in P falciparum has emerged, and has now spread in southeast Asia, slowing therapeutic responses, increasing treatment failure rates, and so jeopardising regional control and elimination eff orts. [9] [10] [11] This situation emphasises the urgent need for new antimalarial drugs if current control and elimination initiatives are to be sustained. 12 Trioxolanes are synthetic antimalarial drugs with a similar peroxide pharmacophore to the artemisinins. 13 The fi rst trioxolane, arterolane (RBx11160/OZ277), 14, 15 proved to be well tolerated in people. [16] [17] [18] [19] Arterolane has been developed and registered in India in combination with piperaquine and was recently approved in seven African countries. The combination has proved highly eff ective in a limited number of clinical trials. 20 Artefenomel (OZ439) is the second synthetic trioxolane to advance to clinical candidate selection (appendix p 14). In a phase 1 study, oral artefenomel (given at doses of 50, 100, 200, 400, 800, 1200, and 1600 mg) was generally well tolerated. 21 The good oral bioavailability, slow clearance, and increased metabolic stability of artefenomel might allow for single-dose cure in combination with a suitable partner drug. 22 A separate phase 1 study found that piperaquine, a potential partner drug, but not artefenomel, prolonged the QTc interval in volunteers. 23 We undertook a dose evaluation of artefenomel in acute malaria, which assessed parasite clearance rate as a measure of antimalarial activity.
Methods

Study design and participants
This phase 2a exploratory, open-label assessment of singledose artefenomel in adult patients with acute uncomplicated P falciparum or Plasmodium vivax malaria was done at the Hospital for Tropical Diseases, Bangkok, Thailand, and the Shoklo Malaria Research Unit (SMRU) on the northwestern border of Thailand. Five single oral doses of artefenomel were planned over the range 100 mg to 1600 mg in cohorts of 20 patients each: two parallel groups of ten patients with P falciparum and ten patients with P vivax malaria (fi gure 1). Cohort sizes allowed for adequate measurement of treatment responses.
Adult male or non-pregnant female febrile patients aged 18-60 years and weighing 40-90 kg who presented with symptomatic malaria (P falciparum or P vivax infections) and 5000-50 000 parasites per μL of blood (microscopy confi rmed) were eligible, provided that they gave fully
Research in context
Evidence before this study Despite progress made during the past few decades, WHO reported in 2014 that malaria kills more than half a million patients per year (2013 data), and parasite resistance against the latest class of antimalarial drugs, the artemisinins, is spreading. New antimalarial drugs are needed to drive the elimination of malaria.
We searched MEDLINE, the Medicines for Malaria Venture website (http://www.mmv.org), the US National Institutes of Health and Australian/New Zealand (ANZCTR) trial registries, and the Cortellis (Thomson Reuters) database for earlier work on artefenomel (OZ439) and similar compounds, with the keywords "artefenomel", "OZ277", "arterolane", "Synriam", "ozonides", "trioxolane", and "synthetic endoperoxides" to search for publications, trial registrations, and other activities by mid-July 2015.
Artefenomel is a new, fast-acting inhibitor of all asexual erythrocytic Plasmodium falciparum stages associated with malaria, and has an in-vitro potency that is similar to clinically used artemisinin derivatives. Its intrinsically unstable peroxide pharmacophore was optimised, resulting in slower elimination compared with artemisinin derivatives and the fi rst-generation ozonide arterolane (OZ277). Two phase 1 human volunteer studies have shown that oral doses of 50 mg, 100 mg, 200 mg, 400 mg, 800 mg, 1200 mg, and 1600 mg artefenomel are well tolerated, and suggest a good safety profi le for the compound.
Added value of this study
To our knowledge, this study is the fi rst to assess the antimalarial activity of artefenomel in patients with malaria. Our study assessed the safety and effi cacy of artefenomel before administration of the defi nitive oral antimalarial treatment. Our fi ndings show that this synthetic peroxide provides rapid parasite clearance in both falciparum and vivax malaria. We have established the pharmacokinetic parameters that will guide optimum dosing and the choice of appropriate partner drugs for antimalarial combination therapy. A retrospective genetic analysis of the malaria parasites in this study suggests that artefenomel-mediated clearance is not substantially aff ected by mutations known to confer partial resistance against artemisinins.
Implications of all the available evidence
Our data show that artefenomel has a good pharmacokinetic and safety profi le, with antimalarial effi cacy against both P falciparum and Plasmodium vivax, clearing the path for further (ongoing) clinical studies. Artefenomel has a longer half-life than other antimalarial endoperoxides, with potential for a single-dose malaria cure when used with a partner drug. Clinical trials in which artefenomel is combined with ferroquine (SSR97193), piperaquine, or DSM265 are being planned or in progress.
See Online for appendix informed written consent. Exclusion criteria were clinical or laboratory signs of severe malaria, 2 inability to tolerate oral drugs, or having received any other antimalarial treatment within 14 days before admission.
The protocol, protocol amendments, written study patient information, informed consent forms, and other appropriate study-related information were reviewed and approved by the ethics committee of the Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand. The study was done in accordance with Good Clinical Practice as required by the International Conference on Harmonisation guidelines and in accordance with country-specifi c laws and regulations governing clinical studies of investigational products. Written, informed consent was obtained from all participants.
Procedures
On admission, patients were examined fully, blood samples were taken for full blood count and routine biochemistry, and the diagnosis of malaria was confi rmed by microscopy. The patients were treated with a single oral dose of artefenomel after a small full-fat milk drink, because food has been reported to aff ect exposure. 21 Patients were monitored closely for the next 36 h. Defi nitive oral antimalarial treatment was given at 36 h, or earlier if parasitaemia showed no reduction after 12 h, or if the reduction after 24 h was lower than 75% (compared with baseline). Defi nitive treatment for patients with P falciparum malaria was mefl oquine 8 mg/kg (base) plus 4 mg/kg artesunate given once daily for 3 days. Patients with P vivax malaria received as defi nitive treatment 25 mg base/kg chloroquine; primaquine (0·5 mg base/kg per day for 14 days) was given for radical cure of vivax malaria, apart from in patients with glucose-6-phosphate dehydrogenase (G6PD) defi ciency, who instead received 0·75 mg primaquine once weekly for 8 weeks.
2 Drugs for defi nitive treatment were sourced locally by the study sites. Patients were considered to have completed the study at day 7, but were reviewed again on day 30 (±2 days) to ensure cure without complications, and in case any adverse event had not resolved.
Patients were recruited sequentially to each dose cohort. 21 The fi rst cohort received a dose of 800 mg. The decision to decrease or increase the dose (within the 100 mg to 1600 mg range) for sequential cohorts was made after a review of the safety data, drug exposure levels, and parasite clearance data for the current cohort. Parasite genotyping for P falciparum kelch mutations was done as described elsewhere.
24 G6PD defi ciency was assessed with the fl uorescent spot test. Artefenomel was manufactured by Unimark, India, and supplied by Penn Pharmaceuticals in glass vials containing 200 mg or 100 mg artefenomel mesylate salt stored at 2-8°C. It was administered as aqueous dispersion.
Blood samples for the assay of artefenomel and its metabolites were obtained before dosing and at 0·5, 1, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96 , and 168 h after dosing. An additional blood sample was withdrawn 4 h after starting defi nitive antimalarial treatment (ie, typically 40 h or 76 h after artefenomel administration). Blood samples (3 mL) were collected into glass tubes containing EDTA (edetic acid) as anticoagulant. Plasma was separated within 30 min of sample collection by centrifugation at 4°C at 1500 rpm for 15 min, and transferred into four polypropylene tubes (three replicates of about 500 mL each). The tubes were stored frozen at -70°C to -80°C until shipment to the laboratory where the analysis was done for the content of artefenomel and its metabolites by liquid chromatography-mass spectrometry. 21 The limit of quantifi cation was 1 ng/mL for all analytes.
Outcomes
The primary endpoint was the natural log parasite reduction rate per 24 h. Secondary endpoints were the fi rst-order parasite clearance rate constant and derived half-life (estimated with the online Worldwide Antimalarial Resistance Network [WWARN] toolkit), parasitaemia reduction times (50%, 80%, 90%, and 99%), parasite clearance time, [26] [27] [28] gameto cytaemia reduction, and fever clearance time. Safety endpoints were incidence, severity, drug-relatedness, and seriousness of adverse events and of laboratory abnor malities. Additionally, clinically signifi cant electro cardiogram (ECG) abnormalities were assessed including prolonged QTcF (>450 ms).
The parasite reduction per 24 h was estimated separately for each patient from a regression model. The relation between parasite counts and time was analysed by fi tting a variable lag phase then a linear decline to the natural logarithm of parasite count versus time relation. The slope of this log-linear relation was the primary endpoint, and all secondary variables related to parasite reduction were derived from this best fi t. The WWARN analytical procedures have been described previously. 26 Fever clearance time was defi ned as the time from artefenomel administration to the fi rst of at least two consecutive normal body temperature measurements (by axillary temperature ≤37·5°C or oral, rectal, or tympanic temperature ≤38°C) obtained within an interval of 6-24 h after artefenomel administration. Incidence of all adverse events was scored with the MedRA (latest version) primary system organ class and preferred term. 29 12-lead ECGs were performed on day 0 pre-dose and after dosing, 2-4 h post-dose, and around 24 h after dosing, and were repeated if clinically indicated.
Statistical analysis
Effi cacy and safety analyses were done by Datamap GmbH (Freiburg, Germany) for all patients who received the study drug. The primary effi cacy endpoint (parasite reduction rate per 24 h) was derived from linear regression fi tting log 10 -trans formed para sitaemia data against their observed times (hours). Only data up to 36 h after dosing and before or equal to the start of defi nitive treatment were used. The timepoints chosen for the regression were those that yield the highest degree of signifi cance when assessing the regression when the number of timepoints are greater than or equal to three. Parasite reduction rate per 24 h and slope were reported with 95% CIs and summarised when the regression fi t had a p value less than or equal to 0·01 and a corresponding R² greater than or equal 0·85. Clearance parameters, expressed as median (range), were obtained with the online WWARN Parasite Clearance Estimator calculator 26 using default settings (40 parasites per μL detection cutoff ). Parasite clearance profi les were scored as valid from criteria used by the online WWARN calculator that allow meaningful parameter estimations. 26 The 24 h parasite reduction rates (SD) were calculated separately (see Methods). Pharmacokinetic analysis was done by Swiss BioQuant AG (Reinach, Switzerland). All pharmacokinetic variables (normally and log-normally distributed) were summarised by arithmetic and geometric means, minimum, median, maximum, SD, and coeffi cient of variation of arithmetic and geometric means. A nonlinear power model was used to assess dose proportionality based on AUC 0-∞ (defi ned as area under the concentration-time curve from 0 h to infi nity) and C max (defi ned as maximum or peak plasma concentration) values for artefenomel. AUCs were calculated by the linear trapezoidal method.
The assessment of dose proportionality was done with SAS/STAT software in a UNIX environment. Mean plots were generated with GraphPad Prism version 5.00. Individual plasma con cen tration-time profi les and noncompartmental pharma cokinetic analysis were done with Professional WinNonlin version 5.2.1. This trial is registered with ClinicalTrials.gov, number NCT01213966.
Role of the funding source
The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
82 patients of Thai, Karen, or Burman origin with acute uncomplicated malaria were enrolled sequentially: 20 in the 200 mg and 800 mg cohorts, and 21 in the 400 and 1200 mg cohorts (fi gure 1). The study took place between Oct 24, 2010 (fi rst patient enrolled), and May 25, 2012. The fi rst cohort was given a dose of 800 mg. The decisions on dose escalation or dose reduction for the subsequent cohorts were taken after a review of the parasite reduction, adverse event, and clinical laboratory data after each dosing cohort. The order that doses were given to cohorts was 800 mg, 400 mg, 200 mg, and fi nally 1200 mg. The proportions of patients with P falciparum or P vivax malaria diff ered between the two study sites; 15% of patients (four of 26) presenting in Bangkok were infected with P falciparum compared with 67% of patients (37 of 55) at the SMRU site; another SMRU patient carried a mixed infection (P falciparum plus P vivax).
One patient (400 mg cohort) withdrew consent and was not treated with artefenomel. Thus, there were 41 evaluable patients with P falciparum (four in Bangkok and 37 in SMRU) and 40 evaluable patients with P vivax (22 in Bangkok and 18 in SMRU, plus the one SMRU patient with mixed infection). No patients required defi nitive antimalarial treatment before the end of the 36 h study period and all recovered uneventfully. Nine patients did not return for the follow-up phase (two in the 200 mg, three in the 400 mg, three in the 800 mg, and one in the 1200 mg cohort). Six (15%) patients with P falciparum and none of the patients with P vivax had G6PD defi ciency. Individual baseline characteristics are shown in table 1 and in the appendix (pp 3-5). The 24 h parasite reduction rates are listed in table 2. These varied from 0·90 to 1·88 for patients with P falciparum, and from 2·09 to 2·53 for those with P vivax, with no clear dose eff ect for either.
All patients responded rapidly to treatment with a mean fever clearance time of 8-30 h (appendix p 6). All investigated doses of artefenomel resulted in similar rates of parasite clearance (fi gure 2, table 2). The median clearance rate constant for P falciparum ranged from 0·12 to 0·17 per hour leading to a 98% reduction in parasite densities by 36 h (appendix p 6 and p 17). The median clearance rate constant for P vivax ranged from 0·22 to 0·30 per hour leading to a 99·6% reduction in parasite densities by 36 h. Estimated median parasite clearance half-life estimates ranged from 4·1 h to 5·6 h for P falciparum and 2·3 h to 3·2 h for P vivax (table 2) . In all cohorts, parasites were undetectable in blood smears at 30-36 h after artefenomel administration in patients with P falciparum and after 18-24 h in patients with P vivax.
In mainland southeast Asia, slow rates of P falciparum parasite clearance after treatment with artesunate are associated with mutations in the kelch propeller domain. 9, 30 The median parasite clearance half-life in the 19 patients with P falciparum parasites with resistance-associated mutations in the kelch 13 propeller region (P441L, N458Y, F446I, P527H, G538V, C580Y, A675A/V, or P667T) was 5·5 h (SD 1·8) compared with 4·4 h (1·8) in patients with parasites with no mutations in the propeller region (fi gure 3; p=0·34; appendix p 13).
There was substantial variability in gametocytaemia over time and between cohorts. The low number of patients with P falciparum malaria with gametocytaemia precluded accurate estimation of gametocyte clearance (appendix p 14). For the patients with P vivax, the median proportional reduction in gametocytaemia was 97·9% in the 800 mg cohort and 90·4% in the 1200 mg cohort at 24 h, and 100% in the 1200 mg cohort at 48 h.
Maximum plasma concentrations of artefenomel were reached about 4 h after administration (table 3, appendix p 15), followed by a multiphasic decline. The C max values were 339 ng/mL, 732 ng/mL, 1710 ng/mL, and 1500 ng/mL for the 200 mg, 400 mg, 800 mg, and 1200 mg doses, respectively. The estimated geometric mean terminal phase t 1/2 for the parent compound ranged from Data are geometric means (coeffi cient of variation) or for t max , median (range). Number of patients: 20 patients each in the 200 mg, 400 mg, and 800 mg cohorts; 21 patients in the 1200 mg cohort. Patients with no assessment at 36 h (n=16) were not taken into account. C max =maximum or peak plasma concentration. t max =timepoint at which the maximal plasma concentration is reached. AUC 0-t =area under the concentration-time curve from 0 h to the last pharmacokinetic sample (96 h). AUC 0-∞ =area under the concentration-time curve from 0 h to infi nity. t 1/2 =estimated terminal phase half-life. *The number of patients may diff er for the variables AUC 0-∞ and t 1/2 . AUC and half-lives were not calculated (NC) when fewer than 70% of patients had valid data. 46·3 h to 62·3 h. The plasma concentration-time profi les for the artefenomel metabolites 21 followed those of the parent compound with the highest exposures for OZ580 and the lowest for OZ567 (table 3) . These metabolites are not thought to contribute signifi cant antimalarial activity. 21 Exposure to all metabolites was lower than for the parent drug. Inter-patient variability was generally high for exposures to artefenomel and its metabolites (appendix p 15). Exposures to artefenomel were similar between patients with P falciparum and P vivax infection and between male and female patients, and there were no apparent eff ects of bodyweight and age.
All patients recovered uneventfully. No patients withdrew because of adverse eff ects (see appendix pp 1-2 and pp 7-9 for a more detailed safety assessment). Two serious adverse eff ects were reported, although neither was deemed drug related.
Most of the adverse eff ects reported in this study were deemed mild in severity by the investigators and no particular pattern was evident. The proportion of patients with at least one moderate, drug-related event was similar between those with P falciparum (43%, 17 of 40 patients) and P vivax mono-infection (33%, 13 of 40 patients). Most changes in laboratory fi ndings and adverse eff ects were mild, reversible, not dose-related, and compatible with acute malaria (appendix pp 7-9). Mild, asymptomatic increases in hepatic transaminases (alanine aminotransferase and aspartate amino transferase) were noted, but were not dose dependent and were never accompanied by hyperbilirubinaemia. Two patients in the 200 mg cohort had a transient alanine amino transferase reading of 83 U/L (normal range 7-40 U/L for alanine aminotransferase and aspartate amino transferase) on days 2 and 7. The highest concentrations for aspartate aminotransferase were 82 U/L, 75 U/L, and 71 U/L for diff erent patients in the 200 mg (2 h and 48 h) and 400 mg (24 h) cohorts, respectively. At least one adverse event was reported for 13 (65%) patients in the 200 mg cohort, for 11 (55%) patients in the 400 mg cohort, for ten (50%) patients in the 800 mg cohort, and for 17 (81%) patients in the 1200 mg cohort. The highest proportion of patients with at least one adverse event and the highest number of events were reported in the 1200 mg cohort for both P falciparum and P vivax. 12 (15%) patients had an asymptomatic rise in plasma creatine phosphokinase (maximum rise 4·9-fold), which did not correlate with dosing (appendix p 8).
Two patients had electrocardiograph QTcF intervals of more than 450 ms (one patient at 2 h and 4 h, and one patient at 24 h). The longest value recorded was 506 ms (pre-dose 423 ms). Both patients were in the 1200 mg cohort. In 18 patients, there were 26 instances of QTcF prolongation of more than 30 ms compared with baseline and three patients had one instance each of QTcF more than 60 ms. There was no signifi cant correlation between QTcF prolongation and concentrations of artefenomel or any of its metabolites (appendix p 11). There were also three instances of reversible right bundle branch block, one in a patient with accompanying T-wave changes compatible with pericarditis evident at baseline, and minor non-specifi c T-wave changes were noted. The cardiac changes did not seem to be dose-related (one in each of the 400 mg, 800 mg, and 1200 mg cohorts) nor were they associated with cardiac-related clinical symptoms or adverse events.
Discussion
The synthetic peroxide artefenomel is being developed as a potential partner drug in an antimalarial combination treatment. The main goal of this fi rst study of antimalarial activity in vivo was to assess the effi cacy of artefenomel in clearing parasitaemia in uncomplicated malaria. The artemisinin derivatives accelerate ring-form parasite clearance providing a readily measurable pharmacodynamic endpoint for dose-fi nding, and this was investigated for artefenomel. Doses as low as 200 mg proved eff ective at eliminating ring-stage parasites rapidly and providing rapid and reliable resolution of symptoms and parasitaemia. 2 Artefenomel is structurally dissimilar to the artemisinins and is eliminated much more slowly, yet it retains their key pharmacodynamic advantages.
The elimination half-life of artefenomel in patients with malaria ranged from 46 h to 62 h, greatly exceeding that of other peroxide antimalarial drugs (arterolane 2-4 h, 19 artesunate 0·8-1·3 h, 31 and dihydroartemisinin 0·9-2 h.
32,33
The pharmacokinetic properties of artefenomel in acute malaria diff ered substantially from those reported earlier in healthy volunteers, 21 with higher concentrations of parent drug and lower concentrations of metabolites, suggesting that acute illness aff ects both distribution and metabolic clearance. The fairly slow elimination and good tolerability up to single doses of 1200 mg suggest that a single-dose combination with one or more other slowly eliminated antimalarial drugs might be curative, particularly against blood-stage vivax malaria. The substantially slower elimination of artefenomel would provide much longer protection against the emergence of partner drug resistance than the protection provided by artemisinin derivatives in the artemisinin-based combination therapies currently in use.
Artemisinin resistance is regarded as the main threat to our attempts to control and eliminate malaria. Artemisinin resistance in P falciparum manifests as slow parasite clearance, delaying clinical recovery, and increased gametocyte carriage. Resistance increases transmissibility and contributes to increased failure rates with artemisinin combination treatments. 9, 26, [34] [35] [36] [37] [38] Artesunate produces clearance rates in falciparum malaria of between 0·23 and 0·39 per hour in sensitive infections and 0·10 per hour in resistant infections. 9, 26 These values correspond to parasite clearance half-lives of about 2-3 h and 6 h, respectively. By comparison, artefenomel provided median parasite clearance rates of 0·12 to 0·17 per hour for P falciparum malaria, corresponding to half-lives of 4·1-5·6 h. Thus, artefenomel provides parasite clearance rates that are slower than those of artesunate on artemisinin-sensitive parasites, and slightly faster than those of artesunate on artemisinin-resistant parasites (see appendix p 12 for a full comparison).
Despite having a similar pharmacophore, the antimalarial activity of artefenomel in infections carrying the kelch 13 propeller mutations strongly linked with artemisinin resistance was not substantially diff erent to its activity in infections that did not have these mutations (median parasite clearance half-life 5·5 h vs 4·4 h). This fi nding suggests that artefenomel might be less aff ected by the mechanisms causing artemisinin resistance and so might have an important therapeutic role as artemisinin resistance worsens. However, this important potential advantage will need to be assessed in larger patient cohorts.
In general, artefenomel was well tolerated. This study included only 81 patients and was not powered to detect risks for wider use of the drug. There were no drugrelated serious adverse eff ects and no signifi cant trends in nausea and vomiting. Although, overall, drug tolerability was good, higher frequencies of adverse events and drug-related adverse events were reported in the 1200 mg cohort than at the lower doses. The most frequently reported adverse eff ect was an asymptomatic increase in plasma creatine phosphokinase concentration. The highest increase (4·9-fold) was seen in a patient in the 200 mg cohort, and there was no dosecorrelation in the 12 readings of increased creatine phosphokinase (appendix p 10). Three instances of reversible right bundle branch block were reported, one in a patient with accompanying T-wave changes compatible with pericarditis evident at baseline. Other minor non-specifi c T-wave changes were reported. The observed cardiac changes did not seem to be dose-related and were not associated with cardiac-related clinical symptoms or adverse eff ects. Such changes may be seen in healthy individuals, 39 as well as in patients with malaria, 40 so the signifi cance of these fi ndings is unclear. Electrocardiograms showed QTcF prolongation com pared with baseline, but this fi nding was expected because malaria is associated with QTcF shortening, 41 and so there is predictable lengthening of the QT interval with recovery. There was no relation between QTcF prolongation and plasma concentrations of either parent compound or metabolites (appendix p 11). Taken together with the absence of QTc prolongation in preclinical studies in dogs, these results suggest that artefenomel does not substantially aff ect the QT interval in patients.
Our preliminary fi ndings suggest that artefenomel has the potential to become an important new antimalarial compound. To prevent or delay the development of parasite resistance against newly introduced drugs, it is common practice to give antimalarial drugs in combination. Potential complementary partner drugs for artefenomel are ferroquine (SSR97193), 42, 43 piperaquine, 32, 44, 45 and DSM265. 46 More information on effi cacy and safety will be needed from additional phase 2 and phase 3 evaluation of artefenomel combination studies.
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